Pharmacogenomics: Relevance for internists?;Pharmakogenomik: Was ist für den internisten relevant?

Internist

Volumn 44, Issue 12, 2003, Pages 1524-1530

  Kruth P ^a   Wehling, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cytochrome P450; Dose adjustment; Enzymes; Genetic polymorphism; Genotyping

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA GLUCURONIDASE; CARRIER PROTEIN; CYTOCHROME P450; CYTOSTATIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PSYCHOTROPIC AGENT;

CARDIOVASCULAR DISEASE; DRUG METABOLISM; GENETIC POLYMORPHISM; GENOTYPE; INCIDENCE; MUTATION; NEUROLOGIC DISEASE; PHARMACOGENOMICS; PREVALENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; ENZYME ACTIVATION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERNAL MEDICINE; METABOLIC DETOXICATION, DRUG; PHARMACOGENETICS; PHARMACOKINETICS; POLYMORPHISM, GENETIC;

EID: 0346881660     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-003-1066-6     Document Type: Review

References (31)

1. Asai S, Miyachi H, Kobayashi H, Takemura Y, Ando Y (2003) Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin. Cancer Sci 94: 210-214
2. Bertilsson L, Dahl ML, Tybring G (1997) Pharmacogenetics of antidepressants: clinical aspects. Acta Psychiatr Scand Suppl 391: 14-21
3. Burchell B (2003) Genetic variation of human UDP-glucuronyltransferase implications in disease and drug glucuronidation. Am J Pharmacogenomics 3: 37-52
4. Chiusolo P, Reddiconto G, Casorelli I et al. (2002) Preponderance of methylentatrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 13: 1915-1918
5. Dalen P, Dahl ML, Ruiz ML, Nordin J, Bertilsson L (1998) 10-Hydroxylation of nortriptyline in white persons with 0,1,2,3 and 13 functional CYP2D6 genes. Clin Pharmacol Ther 63: 444-452
6. Diamond J (2003) The double puzzle of diabetes. Nature 423: 599-602
7. Feuerstein G, Kollek R, Schmedders M, Aken JP van (2003) Irreführende Leitbilder. Zum Mythos der Individualisierung durch pharmakogenetische Behandlungs-konzepte. Eine kritische Anmerkung. Ethik Med 15: 1-8
8. Feuring M, Wehling M, Falkenstein E (2000) Beeinflussung der Arzneimittelwirkung durch Erbfaktoren und Erkrankungen. Internist 41: 332-337
9. Furuta T, Shirai N, Ohashi K, Ishizaki T (2003) Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol 25: 131-143
10. Lewis DF, Watson E, Lake BG (1998) Evolution of the cytochrome P450 superfamily: sequence alignments and pharmacogenetics. Mutat Res 410: 245-270
11. Lin JP, Cupples LA, Wilson PW, Heard-Costa N, O'Donnell CJ (2003) Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study. Am J Hum Genet 72: 1029-1034
12. Liston HL, Markowitz JS, De Vane CL (2001) Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21: 500-515
13. Mayer B, Schunkert H (2000) ACE-Gen-Polymorphismus und kardiovaskuläre Erkrankungen. Herz 25: 1-6
14. Meyer UA (1994) Pharmacogenetics: the slow, the rapid, and the ultrarapid. Proc Nat Acad Sci U S A 91: 1983-1984
15. Oberdisse E (2001) Pharmakokinetik. In: Oberdisse E, Hackenthal E, Kuschinsky K (Hrsg) Pharmakologie und Toxikologie. Springer, Berlin Heidelberg New York, S 26-28
16. O'Toole L, Stewart M, Padfield P, Channer K (1998) Effect of the insertion/deletion polymorphism of the angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 32: 988-994
17. Paul NW, Roses AD (2003) Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social and legal implications. Springer, Berlin Heidelberg New York Tokio, pp 1-7
18. Pickar D (2003) Pharmacogenomics of psychiatric drug treatment. Psychiatr Clin North Am 26: 303-321
19. Poolsup N, Li Wan Po A, Knight TL (2000) Pharmacogenetics and Psychopharmacotherapy. J Clin Pharm Ther 25: 197-220
20. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346
21. Rudnicki M, Mayer G (2003) Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease - pathophysiological considerations. Pharmacogenomics 4: 153-162
22. Sofowora GG, Dishy V, Muszkat M (2003) A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clin Pharmacol Ther 73: 366-371
23. Sparreboom A, Danesi R, Ando Y, Chan J, Figg WD (2003) Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Update 6: 71-84
24. Staessen JA, Wang JG, Brand E et al. (2001) Effects of three candidate genes on prevalence and incidence of hypertension in a Caucasian population. J Hypertens 19: 1349-1358
25. Tafti M, Dauvilliers Y (2003) Pharmacogenomics in the treatment of narcolepsy. Pharmacogenomics 4: 23-33
26. Turner ST, Boerwinkle E (2003) Genetics of blood pressure, hypertensive complications, and antihypertensive drug responses. Pharmacogenomics 4: 53-65
27. Ulrich CM, Yasui Y, Storb R et al. (2001) Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylentetrahydrofolate reductase C677T polymorphism. Blood 98: 2283-2284
28. Wehling M (2000) Arzneimitteltherapie in der Praxis. Immer ein individuelles Experiment. MMW Fortschr Med 44: 27-28
29. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P (1996) Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and S-fluorouracil toxicity. J Clin Invest 98: 610-615
30. Westphal JF, Brogard JM (1997) Drug administration in chronic liver disease. Drug Saf 17: 47-73
31. Yee LJ, Perez KA, Tang J, van Leeuwen DJ, Kaslow RA (2003) Association of CTLA4 polymorphisms with sustained response to interferon and ribavirin therapy for chronic hepatitis C virus infection. J Infect Dis 187: 1264-1271